Table 3.
Top neurological diseases, disorders, and behaviors associated with the 2,544 potential transcriptional targets of RORA
| Function annotation (number of molecules) | Pvalue |
|---|---|
|
Nervous system development and function |
|
| Quantity of neurons (67) |
5.83E-08 |
| Development of brain (102) |
9.01E-08 |
| Morphology of nervous system (161) |
3.96E-07 |
| Morphology of nervous tissue (118) |
5.44E-07 |
| Development of central nervous system (122) |
1.50E-06 |
| Axonogenesis (43) |
1.68E-05 |
| Morphology of nerves (30) |
7.32E-05 |
| Cell-cell adhesion of neurons (6) |
1.48E-04 |
| Morphology of central nervous system (98) |
1.90E-04 |
| Morphology of rhombencephalon (35) |
2.41E-04 |
| Quantity of sensory neurons (19) |
2.81E-04 |
| Development of nerves (19) |
2.81E-04 |
| Abnormal morphology of neurons (51) |
2.85E-04 |
| Morphology of neurons (55) |
3.37E-04 |
| Antinociception (13) |
3.84E-04 |
| Development of neurons (37) |
3.98E-04 |
| Morphology of brain (88) |
4.40E-04 |
| Development of interneurons (7) |
4.56E-04 |
| Migration of neurons (46) |
4.79E-04 |
| Abnormal morphology of cerebellum (21) |
5.58E-04 |
| Development of metencephalon (24) |
5.88E-04 |
| Loss of neurons (29) |
8.01E-04 |
| Long-term potentiation of granule cells (4) |
8.18E-04 |
| Abnormal morphology of cranial nerve (19) |
8.60E-04 |
| Neuritogenesis (83) |
1.11E-03 |
| Development of cerebellum (23) |
1.22E-03 |
| Development of forebrain (45) |
1.26E-03 |
| Fasciculation of nervous tissue (9) |
1.34E-03 |
| Abnormal morphology of granule cells (12) |
1.42E-03 |
| Development of globus pallidus (3) |
1.56E-03 |
| Activation of hippocampus (3) |
1.56E-03 |
| Abnormal morphology of hair cells (9) |
1.84E-03 |
| Morphogenesis of neurites (58) |
1.85E-03 |
| Adhesion of neuronal cells (14) |
1.88E-03 |
| Abnormal morphology of outer hair cells (6) |
2.01E-03 |
| Sensory system development (23) |
2.09E-03 |
| Development of rhombencephalon (28) |
2.15E-03 |
| Chemotaxis of granule cells (4) |
2.23E-03 |
| Guidance of axons (31) |
2.24E-03 |
| Morphology of mechanosensory neurons (10) |
2.49E-03 |
| Cell viability of neurons (39) |
2.51E-03 |
| Analgesia (18) |
2.62E-03 |
| Synaptic transmission of cerebral cortex cells (11) |
3.03E-03 |
| Memory (39) |
3.52E-03 |
| Neurotransmission (71) |
3.75E-03 |
| Development of cranial nerve (11) |
3.79E-03 |
| Cell viability of granule cells (8) |
4.28E-03 |
|
Neurological disease |
|
| Schizophrenia (107) |
8.09E-06 |
| Chorea (117) |
3.23E-04 |
| Huntington's Disease (116) |
4.09E-04 |
| Movement Disorders (183) |
9.11E-04 |
| Dyskinesia (118) |
1.27E-03 |
| Neurological signs (120) |
1.45E-03 |
| Familial transthyretin amyloidosis (3) |
1.56E-03 |
| Seizure disorder (60) |
3.92E-03 |
| Disorder of basal ganglia (135) |
4.31E-03 |
| Polymicrogyria (4) |
4.72E-03 |
|
Behavior |
|
| Behavior (180) |
2.74E-07 |
| Cognition (79) |
1.70E-05 |
| Learning (74) |
3.41E-05 |
| Circling behavior (12) |
1.11E-03 |
| Emotional behavior (42) |
3.04E-03 |
| Memory (39) |
3.52E-03 |
| Spatial learning (33) | 4.23E-03 |
These data were obtained using Ingenuity Pathway Analysis software. P values were calculated using Fisher's exact test, which was performed using the entire set of genes within the Ingenuity Knowledge Base as the reference set.